Clinigen Group (LON:CLIN) had its price objective lifted by Liberum Capital from GBX 1,000 ($13.15) to GBX 1,035 ($13.61) in a research report sent to investors on Monday, Stock Target Advisor reports. They currently have a hold rating on the stock.
A number of other equities research analysts have also weighed in on the company. Peel Hunt reaffirmed a buy rating on shares of Clinigen Group in a research report on Friday. Peel Hunt reaffirmed a buy rating and set a GBX 1,280 ($16.84) target price on shares of Clinigen Group in a research report on Tuesday, October 15th. One equities research analyst has rated the stock with a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the company. The stock presently has an average rating of Buy and an average target price of GBX 1,302 ($17.13).
Shares of LON CLIN opened at GBX 943.52 ($12.41) on Monday. The company has a quick ratio of 0.67, a current ratio of 0.95 and a debt-to-equity ratio of 76.62. The business has a fifty day simple moving average of GBX 895.74 and a two-hundred day simple moving average of GBX 904.99. The firm has a market cap of $1.25 billion and a PE ratio of 235.88. Clinigen Group has a twelve month low of GBX 718.50 ($9.45) and a twelve month high of GBX 1,069 ($14.06).
Clinigen Group plc operates as a specialty pharmaceutical and services company. The company operates through three segments: Commercial Medicines, Unlicensed Medicines, and Clinical Trial Services. The Commercial Medicines segment acquires and licenses commercial medicines and then revitalises them, as well as provides access to licensed and branded generic medicines in the Africa and Asia Pacific region.
Further Reading: Differences Between Momentum Investing and Long Term Investing
Receive News & Ratings for Clinigen Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clinigen Group and related companies with MarketBeat.com's FREE daily email newsletter.